Reply to C. Marchetti et al

Bradley J Monk¹, Keiichi Fujiwara¹, David M O'Malley¹+5

• ¹Bradley J. Monk, MD, GOG Foundation, HonorHealth Research Institute, University of Arizona College of Medicine, Creighton University School of Medicine, Phoenix, AZ; Keiichi Fujiwara, MD, Department of Gynecologic Oncology, Saitama Medical University International Medical Center, Hidaka, Saitama, Japan; David M. O'Malley, MD, Division of Gynecologic Oncology, The Ohio State University, James Cancer Center, Columbus, OH; Robert L. Coleman, MD, US Oncology Research, The Woodlands, TX; Iain A. McNeish, MD, Department of Surgery and Cancer, Imperial College London, London, United Kingdom; Kevin K. Lin, PhD, Molecular Diagnostics, Clovis Oncology Inc, Boulder, CO; Stephanie Hume, PhD, Clinical Development, Clovis Oncology Inc, Boulder, CO; and Rebecca S. Kristeleit, MD, Department of Oncology, Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom.